This week, Bayer announced first-quarter 2025 results. Novo Nordisk and GSK plc announced licensing deals with smaller biotechs. The FDA granted approval to Merck's drug, Welireg, for its third ...
Bayer and Merck & Co, Inc. said heart-failure drug candidate vericiguat didn't meet the primary target of a late-stage study. The German conglomerate on Monday said vericiguat in the phase 3 Victor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback